secwatch.observer — SEC 8-K summary
======================================

Issuer:     IRONWOOD PHARMACEUTICALS INC (IRWD)
CIK:        0001446847
Form:       8-K
Filed at:   2022-01-10T23:59:59+00:00
Accession:  0001104659-22-002490
Event type: earnings
Sentiment:  positive
Materiality: 0.80
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Ironwood expects LINZESS to exceed $1B in 2021 US net sales; raises 2021 adjusted EBITDA guidance to >$230M
--------------------------------------------------------------------------------

- LINZESS U.S. net sales expected to surpass $1B in 2021, achieving blockbuster status.
- 2021 guidance updated: LINZESS growth at high end of 6-8%; total revenue high end of $390-410M.
- Adjusted EBITDA guidance raised to >$230M (from >$210M) for 2021.
- 2022 guidance: LINZESS low single-digit growth; total revenue $420-430M; adjusted EBITDA >$250M.
- Board authorized $150M share repurchase; $27M repurchased in Q4 2021.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1446847/000110465922002490/0001104659-22-002490-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1446847/000110465922002490/tm222198d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-22-002490

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer